Eastern Bank Has $36.92 Million Stock Position in Johnson & Johnson $JNJ

Eastern Bank raised its stake in Johnson & Johnson (NYSE:JNJ) by 125.2% in the second quarter, Holdings Channel reports. The fund owned 145,368 shares of the company’s stock after purchasing an additional 80,814 shares during the quarter. Eastern Bank’s holdings in Johnson & Johnson were worth $36,919,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Blueline Advisors LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $26,000. DecisionPoint Financial LLC lifted its position in shares of Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares during the period. Family CFO Inc bought a new position in Johnson & Johnson in the fourth quarter worth approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received FDA authorization for OTTAVA, its robotic-assisted surgical system, and is preparing for market introduction. Management discussed the system’s design, potential operating-room benefits and commercialization plans, creating a potential new growth platform beyond JNJ’s established pharmaceutical and medical-device businesses. Johnson & Johnson Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System
• Positive Sentiment: Commentary from Jim Cramer characterized OTTAVA’s FDA milestone as a catalyst that improved sentiment toward JNJ after investors initially underappreciated the company’s strong earnings report. The assessment is opinion-based, but it reflects increased visibility for the robotics opportunity. Jim Cramer Analyzes Johnson & Johnson After Surgical Robotics Milestone
• Positive Sentiment: Johnson & Johnson’s oncology business delivered strong second-quarter growth, supported by Darzalex, Erleada and newer cancer treatments. Continued oncology momentum could help offset mature-product pressure and support long-term earnings growth. J&J’s Strong Q2 Oncology Performance Fuels Future Growth Hopes
• Positive Sentiment: Wells Fargo raised its JNJ price target from $272 to $282 and maintained an “overweight” rating, signaling confidence in the company’s earnings outlook and growth initiatives. Wells Fargo Price Target Update
• Positive Sentiment: Reports also highlighted a roughly $3.5 billion biotech transaction or strategic move that expands JNJ’s oncology pipeline, potentially strengthening its future pharmaceutical portfolio. Johnson & Johnson Oncology Pipeline Expansion
• Neutral Sentiment: Market coverage continues to present JNJ as a defensive, dividend-oriented value stock, particularly as technology shares weaken and healthcare attracts broader value-ETF inflows. This may support demand but is not a company-specific catalyst. The S&P 493 Are Staging a Comeback
• Negative Sentiment: OTTAVA must compete with robotic-surgery systems that entered the market earlier, so FDA authorization does not guarantee rapid adoption or meaningful near-term revenue. Investors may also view JNJ’s valuation as demanding after its strong run.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JNJ. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 15th. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Citigroup boosted their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Finally, Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $267.48.

Johnson & Johnson Stock Performance

JNJ stock opened at $254.54 on Tuesday. The company has a market cap of $613.41 billion, a P/E ratio of 29.49, a price-to-earnings-growth ratio of 2.43 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock’s fifty day moving average price is $246.25 and its 200-day moving average price is $238.80. Johnson & Johnson has a 1 year low of $166.64 and a 1 year high of $274.90.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.69 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.